Obese asthma phenotypes display distinct plasma biomarker profiles.
asthma
body mass index
inflammation
obesity
plasma biomarker
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
06
02
2023
received:
13
11
2022
accepted:
13
03
2023
medline:
29
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
ppublish
Résumé
Obese asthma is a complex phenotype and further characterization of the pathophysiology is needed. This study aimed to explore inflammation-related plasma biomarkers in lean and overweight/obese asthmatics. We elucidated levels of inflammation-related plasma proteins in obese asthma phenotypes in the population-based cohort BAMSE (Swedish: Children, Allergy, Milieu, Stockholm, Epidemiology) using data from 2069 24-26-year-olds. Subjects were divided into lean asthma (n = 166), lean controls (n = 1440), overweight/obese asthma (n = 73) and overweight/obese controls (n = 390). Protein levels (n = 92) were analysed using the Olink Proseek Multiplex Inflammation panel. Of the 92 included proteins, 41 were associated with lean and/or overweight/obese asthma. The majority of proteins associated with overweight/obese asthma also associated with overweight/obesity among non-asthmatics. Beta-nerve growth factor (BetaNGF), interleukin 10 (IL-10), and matrix metalloproteinase 10 (MMP10) were associated only with lean asthma while C-C motif chemokine 20 (CCL20), fibroblast growth factor 19 (FGF19), interleukin 5 (IL-5), leukemia inhibitory factor (LIF), tumor necrosis factor ligand superfamily member 9 (TNFRSF9), and urokinase-type plasminogen activator (uPA) were associated only with overweight/obese asthma. Overweight/obesity modified the association between asthma and 3 of the proteins: fibroblast growth factor 21 (FGF21), interleukin 4 (IL-4), and urokinase-type plasminogen activator (uPA). In the overweight/obese group, interleukin-6 (IL-6) was associated with non-allergic asthma but not allergic asthma. These data indicate distinct plasma protein phenotypes in lean and overweight/obese asthmatics which, in turn, can impact upon therapeutic approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Obese asthma is a complex phenotype and further characterization of the pathophysiology is needed. This study aimed to explore inflammation-related plasma biomarkers in lean and overweight/obese asthmatics.
METHODS
METHODS
We elucidated levels of inflammation-related plasma proteins in obese asthma phenotypes in the population-based cohort BAMSE (Swedish: Children, Allergy, Milieu, Stockholm, Epidemiology) using data from 2069 24-26-year-olds. Subjects were divided into lean asthma (n = 166), lean controls (n = 1440), overweight/obese asthma (n = 73) and overweight/obese controls (n = 390). Protein levels (n = 92) were analysed using the Olink Proseek Multiplex Inflammation panel.
RESULTS
RESULTS
Of the 92 included proteins, 41 were associated with lean and/or overweight/obese asthma. The majority of proteins associated with overweight/obese asthma also associated with overweight/obesity among non-asthmatics. Beta-nerve growth factor (BetaNGF), interleukin 10 (IL-10), and matrix metalloproteinase 10 (MMP10) were associated only with lean asthma while C-C motif chemokine 20 (CCL20), fibroblast growth factor 19 (FGF19), interleukin 5 (IL-5), leukemia inhibitory factor (LIF), tumor necrosis factor ligand superfamily member 9 (TNFRSF9), and urokinase-type plasminogen activator (uPA) were associated only with overweight/obese asthma. Overweight/obesity modified the association between asthma and 3 of the proteins: fibroblast growth factor 21 (FGF21), interleukin 4 (IL-4), and urokinase-type plasminogen activator (uPA). In the overweight/obese group, interleukin-6 (IL-6) was associated with non-allergic asthma but not allergic asthma.
CONCLUSION
CONCLUSIONS
These data indicate distinct plasma protein phenotypes in lean and overweight/obese asthmatics which, in turn, can impact upon therapeutic approaches.
Identifiants
pubmed: 36973952
doi: 10.1002/clt2.12238
pmc: PMC10032201
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12238Subventions
Organisme : Region Stockholm, ALF project, Clinical postdoctoral appointment (SK), and database maintenance
Organisme : Hjärt-Lungfonden
Organisme : European Academy of Allergy and Clinical Immunology, Medium-Term Research Fellowship (NHP)
Organisme : Thermo Fisher Scientific, reagents for the allergen-specific IgE analyses
Organisme : Insamlingsstiftelsen Cancer- och Allergifonden
Organisme : H2020 European Research Council
ID : 757919
Organisme : European Respiratory Society (NHP)
ID : LTRF202101-00861
Organisme : Svenska Forskningsrådet Formas
ID : 2016-01646
Organisme : Forskningsrådet om Hälsa, Arbetsliv och Välfärd
ID : 2017-00526
Organisme : Vetenskapsrådet
ID : 2016-03086
Organisme : Vetenskapsrådet
ID : 2018-02524
Organisme : Vetenskapsrådet
ID : 2019-01060
Organisme : Vetenskapsrådet
ID : 2020-02170
Organisme : Astma- och Allergiförbundet
Informations de copyright
© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
Allergy. 2017 Mar;72(3):473-482
pubmed: 27624865
J Allergy Clin Immunol. 2009 Jun;123(6):1391-400.e17
pubmed: 19443020
Sleep Med Rev. 2022 Feb;61:101564
pubmed: 34902822
J Allergy Clin Immunol. 2016 Nov;138(5):1309-1318.e11
pubmed: 27177781
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33184115
J Allergy Clin Immunol. 2018 Mar;141(3):1096-1104
pubmed: 28624608
Eur Respir J. 2020 Jan 2;55(1):
pubmed: 31515408
Am J Respir Crit Care Med. 2023 Feb 15;207(4):406-415
pubmed: 36409973
J Allergy Clin Immunol. 2018 Apr;141(4):1169-1179
pubmed: 29627041
Cardiovasc Diabetol. 2019 Oct 1;18(1):127
pubmed: 31575375
Clin Transl Allergy. 2020 May 25;10:15
pubmed: 32489587
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Clin Transl Allergy. 2022 Aug 17;12(8):e12188
pubmed: 35990418
Lancet Respir Med. 2016 Jul;4(7):574-584
pubmed: 27283230
Clin Exp Allergy. 2018 Jul;48(7):814-824
pubmed: 29665127
J Clin Med. 2021 Jan 06;10(2):
pubmed: 33418879
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
Thorax. 2018 Jun;73(6):538-545
pubmed: 29382799
Cell Immunol. 2017 Feb;312:1-14
pubmed: 28077237
J Eur Acad Dermatol Venereol. 2022 May;36(5):698-704
pubmed: 35032357
Clin Exp Allergy. 2013 Jan;43(1):36-49
pubmed: 23278879
Pharmacol Ther. 2021 Sep;225:107839
pubmed: 33774068
Clin Exp Allergy. 2023 Feb;53(2):186-197
pubmed: 36104952
Eur Respir J. 2016 Oct;48(4):1108-1117
pubmed: 27587551
PLoS One. 2016 Mar 02;11(3):e0150042
pubmed: 26934051
J Endocrinol Invest. 2021 Mar;44(3):599-608
pubmed: 32681464
Eur J Clin Invest. 2018 Sep;48(9):e12997
pubmed: 29995306
Allergy. 2019 Oct;74(10):1835-1851
pubmed: 30953574
Sci Rep. 2021 May 31;11(1):11391
pubmed: 34059769
Eur Respir J. 2019 Dec 12;54(6):
pubmed: 31624112
Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2751-2760
pubmed: 31980524
Sci Transl Med. 2022 Apr 20;14(641):eabl8146
pubmed: 35442706
Allergy. 2019 Jun;74(6):1102-1112
pubmed: 30667542
Thorax. 2021 May;76(5):503-507
pubmed: 33184098
Clin Nutr. 2017 Jun;36(3):861-868
pubmed: 27188262
Am J Respir Cell Mol Biol. 2006 Oct;35(4):503-11
pubmed: 16728704